StockData
Pasithea Therapeutics Corp. logo

Pasithea Therapeutics Corp. (KTTA) stock

KTTANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.51+0.08 (+17.64%)

Close on Nov 18, 2026Market cap $17.07MP/E –Yield –

Pasithea Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Pasithea Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$17.78M. For fiscal 2025 it was -$15.21M. The highest annual figure on record is -$3.17M in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$15.21M–
FY2024Dec 31, 2024-$13.92M–
FY2023Dec 31, 2023-$12.81M–
FY2022Dec 31, 2022-$11.89M–
FY2021Dec 31, 2021-$3.17M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.71M–
Q1 FY2026Mar 31, 2026-$4.79M–
Q4 FY2025Dec 31, 2025-$5.40M–
Q3 FY2025Sep 30, 2025-$2.89M–
Q2 FY2025Jun 30, 2025-$3.87M–
Q1 FY2025Mar 31, 2025-$3.06M–
Q4 FY2024Dec 31, 2024-$2.44M–
Q3 FY2024Sep 30, 2024-$3.12M–
Q2 FY2024Jun 30, 2024-$4.04M–
Q1 FY2024Mar 31, 2024-$4.32M–
Q4 FY2023Dec 31, 2023-$3.29M–
Q3 FY2023Sep 30, 2023-$3.24M–
Q2 FY2023Jun 30, 2023-$3.08M–
Q1 FY2023Mar 31, 2023-$3.20M–
Q4 FY2022Dec 31, 2022-$3.19M–
Q3 FY2022Sep 30, 2022-$4.62M–
Q2 FY2022Jun 30, 2022-$1.94M–
Q1 FY2022Mar 31, 2022-$2.15M–
Q4 FY2021Dec 31, 2021-$1.74M–
Q3 FY2021Sep 30, 2021-$548.44K–
Q2 FY2021Jun 30, 2021-$499.44K–
Q1 FY2021Mar 31, 2021-$381.85K–

More Pasithea Therapeutics figures

See a number that looks wrong?